GlassScriptPhysician profile
David Owen Cook
NPI 1497717987
$3,407.69
in general payments reported to CMS, 2019-2025
30 companies · $547 in 2025
The $547 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $659 · 2021: $323 · 2022: $344 · 2023: $765 · 2024: $545 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,578 · Travel and Lodging: $267 · Education: $13.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.62 |
| Travel and Lodging | $266.85 |
| Education | $13.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $586.07 | 2020 | |
| Procept Biorobotics Corporation | $529.68 | 2023 | Aquabeam Robotic System |
| Endo USA, INC. | $414.66 | 2024-2025 | Xiaflex, Aveed |
| Endo Pharmaceuticals INC. | $371.60 | 2020-2024 | Xiaflex, Aveed, Edex |
| Janssen Biotech, INC. | $312.80 | 2021-2025 | Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $197.33 | 2019-2025 | |
| Axogen | $164.47 | 2024 | Axoguard Nerve Protector, Axoguard Ha+ Nerve Protector, Axoguard Nerve Cap |
| Abbvie INC. | $99.80 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $86.38 | 2024-2025 | Lynparza |
| Astellas Pharma US INC | $78.74 | 2019-2023 | Myrbetriq |
| Sumitomo Pharma America, INC. | $60.50 | 2024 | Orgovyx |
| Ferring Pharmaceuticals INC. | $60.28 | 2024-2025 | Adstiladrin |
| Allergan, INC. | $49.98 | 2019 | |
| Olympus America INC. | $49.69 | 2019-2025 | Itind System |
| Pfizer INC. | $43.80 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $38.24 | 2021 | |
| Boston Scientific Corporation | $37.57 | 2019-2025 | Ams 700 |
| Neotract INC. | $29.96 | 2019 | |
| Davol INC. | $28.57 | 2020 | |
| Laborie Medical Technologies Corp. | $22.76 | 2023 | |
| Teleflex LLC | $20.18 | 2021 | |
| Tei Medical INC. | $18.98 | 2019 | |
| Ambu INC. | $18.83 | 2021-2022 | |
| Axonics, INC. | $17.46 | 2021 | |
| Cook Medical LLC | $16.07 | 2020 | |
| Photocure INC | $14.68 | 2023 | Cysview |
| Urogen Pharma, INC. | $13.68 | 2021 | |
| Travere Therapeutics, INC. | $12.79 | 2019 | |
| Smith+Nephew, INC. | $12.14 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.